Please login to the form below

Not currently logged in
Email:
Password:

Less pain from needles for children

Zingo, a new drug that reduces pain caused by intravenous lines in children aged three to 18 has been launched by Californian biopharmaceutical company, Anesiva
Zingo, a new drug that reduces pain caused by intravenous (IV) lines and blood draws in children aged three to 18 has been launched by Californian biopharmaceutical company, Anesiva.

The drug is an easy-to-administer powder that works within one to three minutes to relieve pain at the site of needle insertion. Currently, anaesthetic creams can take between 30 and 60 minutes to work. The need for timesaving means this application is often sacrificed at the cost of pain to the patient.

"Zingo is the first easy-to-administer, fast-acting local anaesthetic that could lead to a paradigm shift in the approach to venous access procedures such as drawing blood and placing IV lines in children," said Dr William T Zempsky who led the paediatric trials of Zingo.

Anesiva estimates that about 18 million procedures involving IV lines or blood draws are carried out on children in US hospitals each year. Many of these patients receive ongoing and multiple procedures. Zingo will offer a significant improvement in comfort for these patients.

The US Food and Drug Administration (FDA) is reviewing a supplemental New Drug Application (sNDA) to expand Zingo's indicated use to include adults. FDA action is expected by January 2009.

30th June 2008

Share

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
Complete HealthVizion

Complete HealthVizion is a global team of fresh thinkers who aspire to be better every day. We create life-changing medical...

Latest intelligence

Beyond the event
...
Anthill Agency and Actando partnership to Transform Pharma's Digital Skills
Anthill Agency, a leading life sciences digital agency, today announced the launch of the Anthill Academy™ and partnership with Actando's PharmAcademy....
Is the pharma business model ready for precision medicine?
Precision medicine promises to revolutionise patient outcomes and reduce costs for industry but is pharma ready for it? Blue Latitude Health co-founder Head of Strategy Fred Bassett explores the challenges...

Infographics